---
title: Cell and Gene Therapy Catapult vs Oxford Biomedica
slug_a: ct
slug_b: oxb
site: cdmo
review_signal_gate: closed
canonical_path: /compare/ct/oxb
generated_by: BioBM Editorial AI
---

# Cell and Gene Therapy Catapult vs Oxford Biomedica

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Cell and Gene Therapy Catapult (ct) is listed for cdmo. UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.

Services: 13. Modalities: 3. Indications: 4. Locations: 5. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (13).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Oxford Biomedica (oxb) is listed for cdmo. Global viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.

Services: 12. Modalities: 4. Indications: 3. Locations: 17. Certifications: 1. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in locations (17).

Review summary: Review summary withheld until site-level review gate opens.